Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2026-02-25 @ 6:32 PM
Study NCT ID:
NCT01434251
Status:
TERMINATED
Last Update Posted:
2024-12-16
First Post:
2011-09-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Treatment of Hypotension of Prematurity (TOHOP)
Sponsor:
UMC Utrecht
Organization:
Study Overview
Official Title:
Treatment of Hypotension of Prematurity: a Randomized, Non-blinded Cohort Clinical Trial
Status:
TERMINATED
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
It was decided to conclude recruitment due to declining eligibility/recruitment rates and an unrealistically long time span to reach full recruitment.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TOHOP
Brief Summary:
Hypotension in the very preterm infant (gestational age \[GA\] \<32 wks) is a frequently occurring clinical problem. Although no real consensus has been reached on the definition of hypotension in these infants, in clinical practice a mean blood pressure (mean BP) in mmHg lower than the GA age in weeks is considered to be the starting point for anti-hypotensive therapy. However, although an association between neonatal hypotension and mortality/ morbidity exists, there is no evidence of causality between hypotension (meanBP \<GA in completed weeks) and neonatal mortality/morbidity. In addition, using mean BP alone as the indication of treatment of neonatal cardiovascular compromise without taking into consideration the status of tissue perfusion may lead to unnecessary exposure of neonates to vasoactive medication. This medication can be potentially harmful to these extremely vulnerable patients.
The aim of this study is to compare neonatal mortality and short-term neurodevelopmental outcome (cerebral ultrasound during the first 7 days of life, advanced MRI indices of structural brain injury at term GA) and long-term neurodevelopmental outcomes (Bayley scales of infant development III \[BSID-III\] at 24 months) between two groups of very preterm infants presenting with hypotension without clinical and laboratory evidence of compromised tissue perfusion during the first 3 days of life. Hypotension will be defined as the mean BP (in mm Hg) lower than the infant's GA (in weeks). Patients randomized to "Group A" will be treated according to the treatment protocol operative in the Neonatal Intensive Care Unit (NICU) of the University Medical Centre Utrecht (UMCU) while "Group B" will receive no cardiovascular support for hypotension unless they have evidence of compromised tissue perfusion and end-organ function ((i.e. near infrared-monitored regional cerebral oxygen saturation (ScO2) \<50% despite optimized ventilatory support and FiO2 administration, plasma lactate \>6 mmol/L; and/or urine output \<0.6 mL/kg/hour) or mean BP \>5mmHg lower than the current guideline.
The investigators hypothesize that there will be no differences between the two groups concerning short and long-term neurodevelopmental outcomes.
The aim of this study is to compare neonatal mortality and short-term neurodevelopmental outcome (cerebral ultrasound during the first 7 days of life, advanced MRI indices of structural brain injury at term GA) and long-term neurodevelopmental outcomes (Bayley scales of infant development III \[BSID-III\] at 24 months) between two groups of very preterm infants presenting with hypotension without clinical and laboratory evidence of compromised tissue perfusion during the first 3 days of life. Hypotension will be defined as the mean BP (in mm Hg) lower than the infant's GA (in weeks). Patients randomized to "Group A" will be treated according to the treatment protocol operative in the Neonatal Intensive Care Unit (NICU) of the University Medical Centre Utrecht (UMCU) while "Group B" will receive no cardiovascular support for hypotension unless they have evidence of compromised tissue perfusion and end-organ function ((i.e. near infrared-monitored regional cerebral oxygen saturation (ScO2) \<50% despite optimized ventilatory support and FiO2 administration, plasma lactate \>6 mmol/L; and/or urine output \<0.6 mL/kg/hour) or mean BP \>5mmHg lower than the current guideline.
The investigators hypothesize that there will be no differences between the two groups concerning short and long-term neurodevelopmental outcomes.
Detailed Description:
Rationale: Hypotension in the very preterm infant (gestational age \[GA\] \<32wks) is a frequently occurring clinical problem. Although no real consensus has been reached on the definition of hypotension in the very preterm baby, in clinical practice a mean blood pressure (BP) in mmHg lower than the GA age in weeks is considered to be the starting point for anti-hypotensive therapy. However, although an association between neonatal hypotension and mortality and morbidity exists, there is no evidence of causation between hypotension and neonatal mortality and morbidity (including neurodevelopmental outcome at 2 and 3 years of age). In addition, using mean BP alone as the indication of treatment of neonatal cardiovascular compromise without taking into consideration information on the status of tissue perfusion may lead to unnecessary exposure of neonates to forceful vasoactive medications potentially causing harm to these extremely vulnerable patients.
Objective: To compare neonatal mortality and short-term (advanced MRI indices of structural brain injury at 40 weeks' GA) and long-term neurodevelopmental outcomes (Bayley scales of infant development III \[BSID-III\] at 24 months) between two groups of very preterm infants presenting with hypotension without clinical and laboratory evidence of compromised tissue perfusion during the first 72 postnatal hours (3 days). Hypotension will be defined as the mean BP (in mm Hg) lower than the infant's GA (in weeks). Patients randomized to "Group A" will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU) while "Group B" will receive no cardiovascular support for hypotension unless they have a mean BP lower than the current limit minus 5 mmHg and/or evidence of compromised tissue perfusion and end-organ function and thus meet established criteria (see below).
Study design: A single-centre randomized non-blinded cohort study in the NICU at the UMCU of preterm neonates \<30 weeks' gestation during postnatal days 0 to 3.
Study population: All preterm infants with a GA of \<30 weeks admitted on day of postnatal life 0 to the NICU at the UMCU. Patients will be managed according to their randomization to Group A or B until the end of postnatal day 3.
Intervention Patients randomized to "Group A" will be treated for hypotension according to the treatment protocol operative in the NICU at the UMCU. Patients randomized to "Group B" will receive no cardiovascular supportive therapy irrespective of their BP value unless their mean BP is \>5 mmHg below GA in weeks for 30 minutes and/or they have indirect clinical or direct laboratory evidence of tissue hypoperfusion and/or end-organ dysfunction (i.e. rScO2 is \<50% despite optimized ventilatory support and FiO2 administration, plasma lactate \>6 mmol/L; and/or urine output \<0.6 mL/kg/hour).
As CO2 is the most potent regulator of cerebral blood flow (CBF), it is understandable why changes in arterial CO2 tension (PaCO2) has been associated with increased incidence of peri-intraventricular hemorrhage (PIVH) in preterm neonates with significant hypercapnia and with white matter injury (periventricular leukomalacia; PVL) in preterm neonates with hypocapnia during the immediate postnatal period. Therefore, in the present study, ventilation will be closely followed and PaCO2 values monitored and attempted to be kept within normal limits (40-to-50 mmHg) during the first three postnatal days to control for the potential impact of this confounding variable as far as the primary and secondary outcome measures are concerned (see below).
Main study parameters/endpoints: To determine whether refraining (group B) from anti-hypotensive treatment has a negative, positive or no effect on the composite outcome of mortality and neurodevelopmental outcome (determined by BSID-III) at 24 months of age. Secondary outcome measures will include 1) differences between the groups in the incidence of PIVH during the first 7 postnatal days detected by head ultrasound, 2) differences in the incidence of white matter injury PVL and gray matter injury not detected within the first 7 days by ultrasound using advanced MRI parameters of the brain at the adjusted postmenstrual age of 40 weeks as well as the ability to maintain CBF autoregulation during the first three postnatal days.
Objective: To compare neonatal mortality and short-term (advanced MRI indices of structural brain injury at 40 weeks' GA) and long-term neurodevelopmental outcomes (Bayley scales of infant development III \[BSID-III\] at 24 months) between two groups of very preterm infants presenting with hypotension without clinical and laboratory evidence of compromised tissue perfusion during the first 72 postnatal hours (3 days). Hypotension will be defined as the mean BP (in mm Hg) lower than the infant's GA (in weeks). Patients randomized to "Group A" will be treated according to the treatment policy operative in the Neonatal Intensive Care Unit (NICU) of the Wilhelmina Children's Hospital/University Medical Centre Utrecht (UMCU) while "Group B" will receive no cardiovascular support for hypotension unless they have a mean BP lower than the current limit minus 5 mmHg and/or evidence of compromised tissue perfusion and end-organ function and thus meet established criteria (see below).
Study design: A single-centre randomized non-blinded cohort study in the NICU at the UMCU of preterm neonates \<30 weeks' gestation during postnatal days 0 to 3.
Study population: All preterm infants with a GA of \<30 weeks admitted on day of postnatal life 0 to the NICU at the UMCU. Patients will be managed according to their randomization to Group A or B until the end of postnatal day 3.
Intervention Patients randomized to "Group A" will be treated for hypotension according to the treatment protocol operative in the NICU at the UMCU. Patients randomized to "Group B" will receive no cardiovascular supportive therapy irrespective of their BP value unless their mean BP is \>5 mmHg below GA in weeks for 30 minutes and/or they have indirect clinical or direct laboratory evidence of tissue hypoperfusion and/or end-organ dysfunction (i.e. rScO2 is \<50% despite optimized ventilatory support and FiO2 administration, plasma lactate \>6 mmol/L; and/or urine output \<0.6 mL/kg/hour).
As CO2 is the most potent regulator of cerebral blood flow (CBF), it is understandable why changes in arterial CO2 tension (PaCO2) has been associated with increased incidence of peri-intraventricular hemorrhage (PIVH) in preterm neonates with significant hypercapnia and with white matter injury (periventricular leukomalacia; PVL) in preterm neonates with hypocapnia during the immediate postnatal period. Therefore, in the present study, ventilation will be closely followed and PaCO2 values monitored and attempted to be kept within normal limits (40-to-50 mmHg) during the first three postnatal days to control for the potential impact of this confounding variable as far as the primary and secondary outcome measures are concerned (see below).
Main study parameters/endpoints: To determine whether refraining (group B) from anti-hypotensive treatment has a negative, positive or no effect on the composite outcome of mortality and neurodevelopmental outcome (determined by BSID-III) at 24 months of age. Secondary outcome measures will include 1) differences between the groups in the incidence of PIVH during the first 7 postnatal days detected by head ultrasound, 2) differences in the incidence of white matter injury PVL and gray matter injury not detected within the first 7 days by ultrasound using advanced MRI parameters of the brain at the adjusted postmenstrual age of 40 weeks as well as the ability to maintain CBF autoregulation during the first three postnatal days.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: